Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Emerging Significance and Implications of a Durable Complete Molecular Remission in the Treatment of Polycythemia Vera.

Current hematologic malignancy reports - 8 Oct 2025

Duan Minghui, Bose Prithviraj, Hunter Anthony M, Qin Albert, Chang Long, Li Wenxin, Wu Daoxiang, Rampal Raajit K

Abstract excerpt

PURPOSE OF REVIEW: Polycythemia vera (PV) is a Philadelphia chromosome-negative myeloproliferative neoplasm (MPN) caused by a somatic gain-of-function mutation of the Janus kinase2 (JAK2) gene in hematopoietic stem and peripheral blood cells, leading to erythrocytosis which is often accompanied by leukocytosis and thrombocytosis. Historically, PV management has mainly focused on maintaining hematocrit (HCT)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Disease Management
Share to EFS gene

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Janus Kinase 2

Share to Mutation

Share to Phlebotomy

Share to Polycythemia Vera

Share to Remission Induction

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 41060606
DOI: 10.1007/s11899-025-00758-x
PMCID: PMC12508017

Genes

EFS
JAK2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Emerging Significance and Implications of a Durable Complete Molecular Remission in the Treatment of Polycythemia Vera.PMID 41060606Read ↗

Polycythemia vera: from new, modified diagnostic criteria to new therapeutic approaches.Semantic proximity Read ↗

Molecular Characterization of Polycythemia VeraSemantic proximity Read ↗

How I treat polycythemia vera.Semantic proximity Read ↗

Polycythemia vera: diagnosis, clinical course, and current managementSemantic proximity Read ↗

The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era.Semantic proximity Read ↗

Polycythemia vera.Semantic proximity Read ↗

Polycythemia Vera: Rapid Evidence Review.Semantic proximity Read ↗

Advances in Molecular Understanding of Polycythemia Vera, Essential Thrombocythemia, and Primary Myelofibrosis: Towards Precision MedicineSemantic proximity Read ↗

Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera.Semantic proximity Read ↗

Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management.Semantic proximity Read ↗

Polycythaemia vera: molecular genetics, diagnostics and therapeutics.Semantic proximity Read ↗

Recent Advances in the Use of Molecular Analyses to Inform the Diagnosis and Prognosis of Patients with Polycythaemia Vera.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.